Array Biopharma (ARRY) Tops Q2 EPS by 10c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Array BioPharma (ARRY) PT Raised to $23 at Cowen
February 6, 2019 7:56 AM ESTCowen analyst Chris Shibutani raised the price target on Array BioPharma (NASDAQ: ARRY) to $23.00 (from $22.00) while maintaining a Outperform rating.
The analyst commented, "Delivery of another excellent quarter, with F2Q19 MEKTOVI/BRAFTOVI sales of $23MM handily outpacing expectations, bolsters confidence in... More
Array BioPharma (ARRY) PT Raised to $29 at Stifel
February 5, 2019 3:55 PM ESTStifel analyst Stephen Willey raised the price target on Array BioPharma (NASDAQ: ARRY) to $29.00 (from $26.00) while maintaining a Buy rating.
Willey said Q2 confirms the value of the melanoma opportunity.
... MoreArray BioPharma (ARRY) PT Raised to $24 at Jefferies
February 5, 2019 1:47 PM ESTJefferies analyst Eun Yang raised the price target on Array BioPharma (NASDAQ: ARRY) to $24.00 (from $21.00) while maintaining a Buy rating.
Yang notes the company narrowed its Q2 net loss of strong Braftovi/Mektovi sales.
... MoreIncreasing unusual option volume: EOLS MXWL PAGP PBI PKI ARRY ASND NCR AMG MMC
February 5, 2019 5:14 AM ESTIncreasing unusual option volume: EOLS MXWL PAGP PBI PKI ARRY ASND NCR AMG MMC
... More